Current Opinion in Infectious Diseases was launched in 1988. It is part of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of infectious diseases is divided into 11 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Journal's Editors and Section Editors for this issue. EDITORS Thomas F. PattersonThomas F. PattersonDr Thomas F. Patterson received his Bachelor of Arts degree from Baylor University, in Waco, Texas, USA, and his Medical Doctor from the University of Texas Medical School at Houston, Texas, USA. He completed his internship and residency at Vanderbilt University Medical School, in Nashville, Tennessee, USA, and Yale-New Haven Hospital, and a fellowship in infectious diseases at Yale University School of Medicine, New Haven, Connecticut, USA, where he also served as an Assistant Professor of Medicine. Dr Patterson is a Professor of Medicine and Chief, Division of Infectious Diseases and Director of the San Antonio Center for Medical Mycology and serves as the Vice-Chair for Faculty Development in the Department of Medicine. His clinical and research interests focus on the diagnosis and treatment of fungal diseases particularly in immunocompromised hosts. He has been involved in developing new antifungal drugs and in clinical trials of new antifungal compounds and is funded by the NIH and industry for grants and contracts on drug and diagnostic development. During this COVID-19 pandemic Dr Patterson is leading the UT Health Division of Infectious Diseases efforts in clinical management of COVID-19 care and is the site principal investigator for the Adaptive COVID-19 Treatment Trial (ACTT) conducted at University Hospital and supported by the National Institutes of Health to develop safe and effective therapies against COVID-19, and the site principal investigator for the NIH RECOVER initiative to improve outcomes in patients with Long-COVID symptoms. Dr Patterson has published and lectured extensively on fungal infections with over 300 peer reviewed publications, chapters, books and reviews. He has served as member of the American Board of Internal Medicine, Subspecialty Committee for Infectious Diseases and is a Fellow of the American College of Physicians and the Infectious Diseases Society of America, Past-President of the Texas Infectious Disease Society, and past-President, International Immunocompromised Host Society. Robert C. ReadRobert C. ReadProfessor Robert C. Read trained in Medicine at the University of Sheffield, UK and completed his Doctorate Degree at Imperial College London, UK. He is Professor of Infectious Diseases and Honorary Consultant Physician in Infectious Diseases at University Hospital Southampton and is Director of the NIHR Southampton Biomedical Research Centre. Professor Read trained in Infectious Disease and Internal Medicine in various posts in Leeds, Bristol, London and Nottingham, at the National Heart and Lung Institute, Imperial College London, and at the Division of Infectious Diseases, University of California, San Francisco (UCSF) at San Francisco General Hospital, USA, and was previously Professor of Infectious Diseases at the University of Sheffield. His research interests include the pathogenesis and prevention of rapidly lethal infections, notably meningococcal sepsis, influenza and pneumococcal disease. Professor Read has roles in the UK National Institute of Health Research Clinical Research, and is a NIHR Senior Investigator. He has also had leadership roles for the European Society for Clinical Microbiology and Infectious Diseases, and the Infectious Disease Society of America. He is a member of the UK Joint Committee for Vaccines and Immunisation (JCVI). He is Editor-in-Chief of the Journal of Infection. SECTION EDITORS David DockrellDavid DockrellProf. Dockrell is a graduate of Trinity College Dublin, Ireland. After initial medical training in Dublin he moved to the Mayo Clinic, USA where he completed general internal medicine and infectious disease training. During this period, he developed his subspecialty interests in HIV medicine and infections in immunocompromised hosts. His laboratory interests have focused on the role of macrophages in host defense and in the pathogenesis of HIV and bacterial infection. In particular, his laboratory has investigated the role of cell death programs in enhancing microbial killing, with a particular focus on pneumococcal disease and other respiratory infections, and on how viruses such as HIV can manipulate these responses. He has also worked as a clinical trialist particularly in HIV medicine and in vaccine studies. Prof. Dockrell is a former Wellcome Trust Senior Fellow at the University of Sheffield, UK, and now leads the Shield consortium developing host-based therapies to combat antimicrobial resistance. Since 2016 he has been Chair of Infection Medicine at the University of Edinburgh, Scotland. He has authored over 100 publications and book chapters. He has contributed to several national treatment guidelines and serves on a number of research panels and professional bodies. Joseph A. DuncanJoseph A. DuncanJoseph A. Duncan is a Professor of Medicine and Pharmacology at the University of North Carolina School of Medicine in Chapel Hill, NC, USA. He received his M.D. and Ph.D. degrees from the University of Texas Southwestern Medical School in Dallas, TX, USA before pursuing clinical training in Internal Medicine and Infectious Diseases at the University of North Carolina at Chapel Hill, NC, USA. Dr Duncan served as the Director of the Infectious Diseases Training Program before becoming the Director of the Physician Scientist Training Program for the Department of Medicine in 2015. Early in his career, Dr Duncan clinically focused on diagnosis and management of Sexually Transmitted Infections while developing an active research program studying N. gonorrhoeae infection. He continues to lead an active research group focused on innate immune signaling as well as the pathogenesis and immune responses to N. gonorrhoeae infection. Dr Duncan has co-authored 50 articles in peer reviewed journals and is a Fellow of the Infectious Diseases Society of America and was elected to membership in the American Society of Clinical Investigation in 2020.